APAdam Joseph Prus

Adam Joseph Prus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adam Joseph Prus has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Discriminative stimulus properties of two training doses of gabapentin in rats: Substitution by pregabalin, diazepam, and pentobarbital.

    by Adam J. Prus, Madeline T. Van Fossen, Alexandria N. Iannucci, Alexia G. Dalton, Joshua N. Prete

    Gabapentin is used for the treatment of many conditions, including seizures, pain, and anxiety. Increasing reports of nonprescribed use suggest that gabapentin may elicit positive subjective effects. The present study was conducted to examine the subjective effects of gabapentin using rats trained to discriminate either a 30.0 mg/kg or 300.0 mg/kg dose of gabapentin versus vehicle on a two-choice drug discrimination task. Both doses of gabapentin were established as discriminative stimuli, and the 300.0 mg/kg dose was more readily established compared to the 30.0 mg/kg dose. Full substitution (> 80% gabapentin-lever responding) occurred by the training drug and by the gabapentinoid compound pregabalin. Partial substitution (> 20% gabapentin-lever responding) was shown by the opioid compounds morphine and fentanyl, and dose combinations of the opioid receptor antagonist naltrexone with the gabapentin training doses reduced the percentage of gabapentin-lever responding to below 80%. Partial substitution for both training doses of gabapentin occurred with the cannabinoid Δ⁹-tetrahydrocannabinol. The barbiturate compound pentobarbital and the benzodiazepine compound diazepam were only tested for substitution for the 300.0 mg/kg dose of gabapentin and these compounds produced full substitution. These findings demonstrate that gabapentin establishes a robust discriminative cue and exhibits stimulus effects closely similar to pregabalin, pentobarbital, and diazepam. Since pregabalin, pentobarbital, and diazepam carry a risk of problematic use and are classified as controlled substances, further evaluations of gabapentin's risks in this regard are warranted. (PsycInfo Database Record (c) 2024 APA, all rights reserved).


  • Open Access

    Discriminative Stimulus Effects of 30.0 and 300.0 mg/kg Gabapentin in Rats: Substitution Testing with Morphine and Fentanyl

    by Alexia G. Dalton, Madeline T. Van Fossen, Alexandria Iannucci, Joshua Prete, Taylor Galaszewski, Dillon S. Shekoski, Bethany E. Beavers, Adam J. Prus

    ID 56087 Poster Board 416 Gabapentin is a blocker for Ca2+ channels that contain an α2Δ-1 or α2Δ-2 subunit and is prescribed for neuropathic pain, anxiety, fibromyalgia, and epilepsy. There are increasing reports of abuse with gabapentin, particularly when also used with opioids. These observations suggest that gabapentin may produce positive subjective effects and that these effects may be similar, to some extent, with opioids. In order to examine the subjective effects of gabapentin, the present study utilized a drug discrimination procedure in 22 male adult Sprague Dawley rats trained to discriminate either a 30.0 (30GPN) or 300.0 mg/kg dose (300GPN) of gabapentin versus saline in a two choice operant task for food reinforcement. All rats met the training criteria, consisting of 5 out 6 consecutive sessions of at least 80% condition-appropriate responding. Gabapentin produced full-substitution (>80% drug-lever responding) for 30GPN beginning at a 15.0 mg/kg dose and for 300GPN beginning at a 100.0 mg/kg dose. Morphine produced partial substitution (>20% drug-lever responding) for both training doses, with a 5.0 mg/kg dose of morphine producing partial substitution for both 30GPN (40.9% drug-lever responding) and 300GPN (31.7%). A 10.0 mg/kg dose of morphine also partially substituted for the lowest training dose, 30GPN (64.8%), which significantly reduced response rates (0.5 responses per second [RPS]), but this dose was highly rate suppressant for the 300GPN group (0.02 RPS), which precluded determination of percent drug responding for this dose. A 0.08 mg/kg dose of fentanyl partially substituted for 30GPN (45.6%) and for 300GPN (33.2%). Pretreatment with a 3.0 mg/kg dose of the opioid receptor antagonist naltrexone partially blocked the discriminative stimulus effects of 30GPN (69.5%) and 300GPN (69.8%). The present findings indicate that gabapentin can be readily established as a discriminative cue and that the properties of this cue may be partially mediated by opioid receptors.

  • Open Access

    Assessment of Dextromethorphan on Compulsive Behavior Using the Schedule-Induced Polydipsia Paradigm in Rats

    by Madeline T. Van Fossen, Alexia G. Dalton, Bethany E. Beavers, Dillon S. Shekoski, Taylor Galaszewski, Adam J. Prus

    ID 27875 Poster Board 112 Dextromethorphan (DM) is a sigma1 receptor agonist, 5-HT2A receptor agonist, and NMDA receptor antagonist FDA-approved for pseudobulbar affect and, in combination with the dopamine reuptake inhibitor bupropion, for the treatment of major depressive disorder. Antidepressant drugs that exhibit pharmacological actions similar to DM can attenuate symptoms of obsessive-compulsive disorder. The present study aimed to evaluate the effects of DM in rats using the schedule-induced polydipsia procedure, a model of compulsive behavior. In this paradigm, food-, but not water-, restricted animals drink excessive amounts of water when food is delivered on a fixed schedule. This study examined male Wistar rats (food restricted to 85% of free-feed weights) during 60 min sessions with fixed-time 60 second schedules and free access water. Following 20 consecutive daily training sessions, rats were divided into high or low drinker groups. DM (15.0 - 60.0 mg/kg) dose-dependently reduced water consumption and frequency of licks in both the low and high drinker groups. DM reduced food-receptacle head entries in only the low drinker group. Further, the 5-HT2A/2C agonist DOI (0.5 - 2.0 mg/kg) also inhibited water consumption in both low and high drinkers and reduced frequency of head entries in only the low drinker group. Based on these findings, DM may be effective for treating compulsive behavioral disorders and these effects may be facilitated by activation of 5-HT2A receptors.

  • Lack of sex and estrous stage effects on compulsive behavior assessed using a schedule-induced polydipsia procedure in rats

    by Min Park-Oates, Adam J. Prus

    Preclinical behavior models used for screening pharmacological treatments for mental disorders have generally used only male research subjects, and for studies that have included female subjects, few have utilized sex as a study variable. In fact, many mental disorders vary by prevalence and symptomatology between sexes, creating a need to evaluate established subject models for sex differences. Compulsive behavior is a feature shared across many mental disorders and effective treatments have been examined pre-clinically using the schedule-induced polydipsia procedure in rats. Drugs effective for reducing polydipsia include psychostimulants, such as d-amphetamine. Virtually no studies have examined sex differences using this procedure. For the present study, male and female rats were examined in the schedule-induced polydipsia paradigm. Rats were food-restricted and trained on a fixed-interval food reinforcement schedule and given free access to water during experimental sessions. Estrous stages were assessed during training and test sessions. The psychostimulant d-amphetamine was also tested once stable water consumption occurred. Excessive water intake developed over the course of training. Females required significantly more sessions to reach a stable level of drinking. Treatment with d-amphetamine (1.0 mg/kg, but not 0.25 or 0.5 mg/kg) significantly reduced drinking in both male and female rats. No sex differences were observed across other study variables including comparisons between diestrus and proestrus stages. Overall, these findings suggest that schedule-induced polydipsia procedures that employ similar methods can produce results generalizable across male and female subjects.


  • Assessment of antidepressant-like effects of dextromethorphan on differential reinforcement of low-rate 72-s performance in rats

    by Cayla J. Lynch, Adam Joseph Prus

    The effectiveness of ketamine for treatment-resistant depression along with several other clinical advantages, such as rapid onset and reduced adverse effects associated with serotonin transporter inhibition, has garnered interest in other similar acting psychedelics as novel antidepressant drugs. The antitussive dextromethorphan exhibits glutamate N-methyl-d-aspartate receptor antagonism, sigma-1 receptor agonism, and serotonin reuptake inhibition, which has exhibited antidepressant effects in limited human studies and animal models. The present study sought to further examine dextromethorphan using a differential reinforcement of low-rate 72-s schedule, which can be used to screen antidepressant drugs, in male and female rats. The tricyclic antidepressant drug imipramine and the psychostimulant d-amphetamine also were examined. Sex differences were not shown for baseline performance or for the drugs tested. Further, performance did not differ between the estrus and diestrus stages. Dextromethorphan alone and with quinidine produced an antidepressant-like effect by reducing the number of responses emitted, increasing the number of reinforcers earned, and shifting inter-response times to the right, although significant response suppression occurred at these doses. An antidepressant-like effect was shown with imipramine, but d-amphetamine increased the number of responses emitted and did not affect the number of reinforcers earned. The present findings provide additional support for antidepressant effects produced by dextromethorphan.


  • Open Access

    Discriminative Stimulus Effects of Gabapentin

    by Michael Ryan Zuidema, Lindsey Kay Galbo, Alex Duncan Lekander, Lea Esterline, Adam Joseph Prus

    Gabapentin (Neurontin) is synthetic analog of GABA that functions as a voltage‐gated calcium channel (VDCC) blocker and is FDA approved for the management of neuropathic pain and seizure disorders. While not a controlled substance, gabapentin misuse is associated with illicit opioid use, suggesting, along with anecdotal reports, that gabapentin may elicit positive subjective effects. The present study was conducted to examine the subjective effects of gabapentin using rats (N=10) trained to discriminate a 30.0 mg/kg dose of gabapentin (60 min pretreatment time) versus saline in a two‐choice drug discrimination task. The discrimination was acquired in all 10 animals ( M = 67.4 sessions, +/− 7.2 SEM ). A time course assessment using the gabapentin training dose revealed full substitution (> 80% Gabapentin‐appropriate responding) at 30 and 60 minutes post‐injection. In addition to the training dose, full substitution also occurred for a 60 and 120 mg/kg dose of Gabapentin. Full substitution was shown for the barbiturate and GABA A receptor positive modulator pentobarbital and for the gabapentin analog and VDCC blocker pregabalin. Partial substitution was shown with the psychostimulant d‐amphetamine and the anxiolytic drug and 5‐HT 1A partial agonist buspirone. The present findings demonstrate gabapentin's discriminative stimulus effects appear to be primarily mediated by GABA A receptors and VDCC blockade and partially mediated by dopamine and 5‐HT receptors. Full substitution by pentobarbital and partial substitution by amphetamine suggests the potential for positive subjective effects produced by gabapentin. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .

  • The Neurotensin NTS1Receptor Agonist PD149163 Produces Antidepressant‐Like Effects in the Forced Swim Test: Further Support for Neurotensin as a Novel Pharmacologic Strategy for Antidepressant Drugs

    by Lawrence M. Carey, Remington J. Rice, Adam J. Prus

    Preclinical Research Neurotensin is a nonbrain penetrant neuropeptide neurotransmitter that alters dopaminergic and serotonergic neurotransmission. Previous animal behavioral studies have demonstrated that intra‐ventral tegmental administration of neurotensin and system administration of the selective neurotensin NTS1receptor agonist, PD149163 produce antidepressant‐like effects in a forced swim test and a differential reinforcement of low rate task, respectively. The present study sought to expand upon these past findings by assessing systemic administration of PD149163 in a forced swim test, a primary antidepressant preclinical screening model, in mice. The tricyclic antidepressant drug imipramine was tested for comparison, and both compounds were also assessed in an open field test. Both PD149163 and imipramine reduced time spent immobile, an antidepressant‐like effect, in the forced swim test. The highest dose of each compound significantly reduced locomotor activity. These findings provide further evidence for the putative antidepressant effects for PD149163 and suggest that NTS1receptor activation may be a novel pharmacologic strategy for antidepressant drug development. Drug Dev Res 78 : 196–202, 2017.